HHS to Back Emergent BioSolutions’ Ebola Drug Development With Potential $704M Award

Emergent BioSolutions (NYSE: EBS) will further develop a licensed drug against Ebola under a potential 10-year, $704 million contract from the Department of Health and Human Services.